Taysha Gene's Epilepsy Candidate Shows Encouraging Action In Preclinical Studies

Trending Investment Opportunities

Taysha Gene Therapies Inc TSHA announced a late-breaking abstract and poster presentation on preclinical data for TSHA-105 for SLC13A5-related epilepsy.
Data were shared at the American Epilepsy Society Annual Meeting.
In knockout mouse models of SLC13A5 deficiency, treatment with TSHA-105 resulted in normalized citrate levels, reduced seizure activity, and improved survival regardless of age.
"These preclinical results suggest that TSHA-105 can demonstrate functional improvements with intervention at any age in a potentially safe and tolerable manner which would be expected to translate into a meaningful benefit to patients with SCL13A5 deficiency," said Suyash Prasad, Chief Medical Officer and Head of R&D Taysha.
The Company plans to submit an IND/CTA filing in 2022.
Price Action: TSHA shares closed 10.04% higher at $14.25 during after-hours trading on Monday.

Momentum90.12

GrowthN/A

QualityN/A

Value5.83

Short

Medium

Long